AtriCure Targets $1 Billion as Pain Management and AFib Trials Fuel Growth

AtriCure is targeting $1 billion in revenue by 2030 , after reporting roughly 18% five-year compound growth, a 77% gross margin and three consecutive quarters of net income. Its current annual revenue outlook is approximately $602 million to $610 million. The pain-management business is a major growth driver: procedure volume rose about 25% in the latest quarter, helped by the cryoSPHERE MAX launch, while expansion into amputation procedures offers additional upside. Clinical trials could significantly expand AtriCure’s market : BoxX-NoAF is expected to complete enrollment by year-end with data due by mid-2027, while the larger LeAAPS trial could support broader AtriClip adoption if its stroke-reduction results are favorable.

AtriCure NASDAQ: ATRC said it is seeing continued growth across its atrial fibrillation, left atrial appendage management and postsurgical pain-management businesses, supported by new product adoption, expanding procedure volumes and progress in clinical trials. Speaking at the Canaccord Genuity Global Growth Conference, President and CEO Mike Carrel said the company focuses on treating complex atrial fibrillation, or AFib, and pain after surgery. Its portfolio includes ablation products, AtriClip devices for managing the left atrial appendage to reduce stroke risk, and cryoablation technology designed to temporarily block pain signals after invasive procedures.

Carrel said AtriCure has produced approximately 18% compound annual growth over the past five years and has begun generating profit and cash flow. He cited 77% gross margin in the most recent quarter and net income for a third consecutive quarter. The company has guided for annual revenue of roughly $602 million to $610 million, he said, while its long-range plan calls for $1 billion in revenue and 20% adjusted EBITDA by 2030.

CFO Angela Wirick said thoracic procedures remained the primary growth driver in AtriCure’s U.S. pain-management business during the second quarter. The launch of the cryoSPHERE MAX product, which cuts freeze time for certain procedures in half, has accelerated procedure volumes, she said. Wirick said pain-management volume rose about 25% during the quarter, while the number of accounts grew approximately 12%, indicating that surgeons are using the technology in more procedures within existing accounts. She said market penetration is around 20% in thoracic procedures and remains substantially lower in sternotomy and amputation applications. Carrel said the company has more than 2,000 systems installed in thoracic centers across the U.S. and more than 100 field personnel across clinical and sales roles supporting the pain business. He said the company views its installed infrastructure, clinical knowledge and field presence as competitive barriers, alongside its ability to manufacture systems at scale. The company is also expanding cryotherapy into amputations through its cryoXT device. Carrel described the amputation opportunity as being in its early stages, while Wirick said AtriCure sees favorable momentum across pain-management applications.

Wirick said product mix was the largest contributor to the company’s 77% gross margin in the latest quarter, as newer U.S. product launches represented a higher share of revenue and carried favorable margins. Geographic mix also contributed, she said, as U.S. margins are higher than those generated in international markets. She said a new manufacturing facility is expected to come online during the current quarter, which could bring gross margin back toward the 76% range in the ne...